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Abstract
Hypertension is a major cause and contributor to stroke, heart and kidney disease. Despite the
development of an arsenal of medication to treat hypertension over the past half-century,
adequate treatment continues to be a major problem in the United States. The Third National
Health and Nutrition Examination Survey (NHANES-III) shows that only 29% of hyperten-
sive patients reach a blood pressure less than 140/90 mm Hg. Resistant hypertension is defined
as a blood pressure greater than 140/90 mm Hg despite a rational combination of three or more
blood pressure medications including a diuretic. The prevalence of true resistant hypertension in
hypertension clinics is only about 11–13%. Higher prevalence rates are evident in populations
with evidence of end-organ disease such as cardiac or renal disease where lower blood pressure
targets have now been established. Ascertaining the possible cause(s) for resistant hypertension
is a challenge to all clinicians, but critical in eventual determination of a therapeutic solution.
The following review will hopefully help guide clinicians in their discernment of causes and
potential treatments for resistant hypertension. The diagnosis and treatment of the more com-
mon secondary causes will be described and treatment options for patients with resistant hyper-
tension are discussed. Newer options, some still under clinical investigation, will be described
and their future utility will be discussed. (Cardiol J 2007; 14: 329–339)
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Introduction
Hypertension is a major cause and contributor
to stroke, heart and kidney disease. Despite the
development of an arsenal of medication to treat
hypertension over the past half-century, adequate
treatment continues to be a major problem in the
United States. The Third National Health and Nu-
trition Examination Survey (NHANES-III) shows
that only 29% of hypertensives reach a blood pres-
sure less than 140/90 mm Hg [1]. Despite major
reductions in age-adjusted death rates from coro-
nary heart disease and stroke, these continue to be
the leading and third most common causes of death,
respectively, in the United States [2]. In particu-
lar, for every 20 mm Hg increase in systolic blood
pressure or 10 mm Hg in diastolic blood pressure,
there is a doubling of stroke and coronary artery
disease death rates [3]. Kidney Failure related to
hypertension continues to grow, especially among
the African-American population [4, 5]. The risk of
both stroke and renal disease is higher in African-
Americans compared to Caucasians. This may have
more to do with the duration of hypertension than
it does the severity of hypertension in this popula-
tion given evidence that African-Americans tend to
develop hypertension at a much earlier age [6–8],
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possibly related to lower birth weight [9]. Addition-
ally, hypertension and its vascular effects may go
undetected in this population given the non-dipping
pattern that is more prevalent in these individuals
[10, 11].
The increasing body of evidence demonstrat-
ing the critical role of hypertension in the develop-
ment of end organ disease has lead to a significant
lowering of recommended blood pressure targets
by the American Heart Association, the American
Diabetes Association and the National Kidney Foun-
dation [12–14]. In spite of these lowered targets,
clinical benefit can only be realized with successful
blood pressure reduction.
Definition of resistant hypertension
Resistant hypertension is defined as a blood
pressure greater than 140/90 mm Hg despite a ra-
tional combination of three or more blood pressure
medications including a diuretic [15]. The preva-
lence of true resistant hypertension in hypertension
clinics is only about 11–13% [16]. Higher preva-
lence rates are evident in populations with evidence
of end-organ disease such as cardiac or renal dis-
ease where lower blood pressure targets have now
been established. In a study by Muxfeldt et al, only
56% of individuals diagnosed with resistant hyper-
tension in an office setting were demonstrated to
be truly hypertensive [17]. The presence of left
ventricular hypertrophy, chronic kidney disease,
and other evidence of vascular disease increase the
likelihood of true resistant hypertension. Attenua-
tion of the normal 10–20% reduction in nocturnal
blood pressure (i.e. a “non-dipping” pattern) ob-
served by ambulatory blood pressure monitoring is
also suggestive of true resistance.
Confirmation of resistance depends upon ex-
clusions of both pseudo-hypertension and labile or
“white coat” hypertension. The former is usually
a result of inaccurate blood pressure recordings due
to improper sizing of the blood pressure cuff. The
width of the cuff bladder should cover 40–46% of
the arm circumference and the length should en-
circle 80% of the arm’s circumference [18, 19].
Blood pressure cuffs that are inappropriately small
can result in falsely elevated blood pressure record-
ings due to inadequate compressive occlusion of the
brachial artery. The error of underestimation of
pressure resulting from “overcuffing” is less than
the error of overestimation of blood pressure from
a cuff bladder that is too small. In patients with
morbid obesity in whom a short upper arm length
is coupled with a very large arm circumference, the
cuff can be placed on the forearm with the systolic
pressure alone palpated or Korotkoff sounds aus-
culted over the radial artery. As with any measure-
ment of blood pressure, the sphygmomanometer
and thus the part of the arm where blood pressure
is being measured must be at the level of the heart.
Conversely, labile hypertension refers to real
increases in blood pressure usually driven by anx-
iety-mediated augmentation in central sympathet-
ic nervous traffic. Blood pressures return to nor-
mal or significantly lower levels in non-stressful
situations. Exclusion of this phenomenon can only
be done using out-of-office blood pressure measure-
ments such as home or ambulatory blood pressure
monitoring.
Ascertaining the possible cause(s) for resist-
ant hypertension is a challenge to all clinicians, but
critical in eventual determination of a therapeutic
solution. The following review will hopefully help
guide clinicians in their discernment of causes and
potential treatments for resistant hypertension.
Causes and treatment
of resistant hypertension
In general, the causes of resistant hypertension
can be divided into four categories. These include
endocrine disorders, kidney-related disorders, life-
style-related disorders, and drug-related issues
(Table 1). Treatment is directed at the specific con-
tributing cause.
Critically important in any work up of refrac-
tory hypertension are historical and physical exam
findings that may lead one to a diagnosis. Addition-
ally, an initial battery of routine laboratory tests
frequently provides clues to the potential cause for
poor blood pressure control (Table 2). These diag-
nostic clues can increase the pretest sensitivity
during further screening for endocrine and kidney-
related cause for hypertension.
Endocrine disorders
The major endocrine causes of resistant hyper-
tension include hyperaldosteronism, Cushing’s syn-
drome and pheochromocytoma.
In addition to severe hypertension, clinical
clues to the possible presence of hyperaldosteronism
or “Conn’s syndrome” include spontaneous or diu-
retic-induced hypokalemia and metabolic alkalosis.
The absence of either of these laboratory findings
does not exclude the diagnosis, however. Current-
ly, the best screening test for hyperaldosteronism
is the morning ambulatory plasma aldosterone con-
centration (PAC) to plasma renin activity (PRA)
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ratio. If the ratio is greater than 20 ng/dL per ng/mL
per hour in the setting of a PAC level greater than
15 ng/dL, then hyperaldosteronism is suggested [20].
This has been demonstrated in some studies to have
a 90% sensitivity and specificity.
Ideally, the patient should be off angiotensin
converting enzyme inhibitors (CEI) and angiotensin
receptor blockers (ARB), both of which can increase
plasma renin activity, as well as beta-blockers
(which can decrease PRA) when the test is per-
formed. However, the PAC/PRA ratio has been
shown to be valid even with sodium loading/diuresis
or ongoing antihypertensive therapy, save for aldos-
terone antagonists or high dose amiloride [21, 22].
If the patient is on an aldosterone receptor antago-
nist, it should be discontinued for six weeks prior to
performing any studies on plasma or urinary aldos-
terone levels. Given the expected increase in PRA
induced with either of a CEI or ARB, an increased
PAC/PRA ratio on either agent in the setting of an
elevated PAC deserves further evaluation.
As hypokalemia can suppress aldosterone se-
cretion, it should be corrected before any aldoster-
one testing. PAC and PRA levels should ideally be
drawn in the morning. In the presence of a sugges-
tive PAC/PRA screening test, the clinician should
obtain a 24-hour urine for creatinine (as a bench-
mark of collection adequacy), aldosterone, sodium,
and potassium. The test should be done after the
patient has been on a high salt diet (or sodium chlo-
ride tablets 2 g TID) for three days documented by
a total urinary sodium of > 200 mEq/day in the
24 hour collection [20, 21]. Ideally, patients should
































Table 2. Classic clinical clues to secondary hypertension*.
Cause History Physical Laboratory




Cushing’s syndrome Muscle weakness; Striae, trunkal obesity, Glucose intolerance
menstrual irregularities  cervical and supra- (diabetes mellitus)
clavicular fat pads
Pheochromocytoma Headaches; episodic NA NA
palpitations, clamminess;
weight loss
Chronic kidney NA NA Estimated GFR
disease < 60 cc/min
Renal artery Episodes of flash Bruits over multiple Reduced GFR
stenosis pulmonary edema; vessels (carotid, subclavian, or its unexplained
smoking; diffuse   epigastric, femoral)   accelerated decline;
vascular disease spontaneous hypokalemia
*Patients may have these secondary causes of hypertension without necessarily manifesting any of these findings
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be off diuretic therapy to enhance volume expan-
sion. A urinary aldosterone level in excess of
14 mcg/day with a urinary potassium > 30 mEq/day
in the salt loaded state is virtually diagnostic. A plas-
ma aldosterone concentration > 10 ng/dL obtained
after a two-liter infusion of normal saline adminis-
tered over four hours while the patient is supine is
an alternative diagnostic test [22].
After biochemical confirmation of non-sup-
pressible aldosterone secretion, anatomic localiza-
tion should be attempted using thin-cut computed
tomography (CT) imaging. Presence of a unilateral
adenoma should result in laparoscopic resection in
younger hypertensive patients (< 40 years old),
whenever the gland is large (> 4 cm) and dense, or
when ther are findings suggestive of possible ma-
lignancy, irrespective of age. Failure to discern an
adenoma by CT imaging does not exclude the pres-
ence of a microadenoma and should prompt long-
term treatment with specific aldosterone antagonism
with either spironolactone or eplerenone [23, 24].
Adrenal vein sampling can provide direct evidence
of anatomic and biochemical correlation that should
ideally be performed in any individual prior to an-
ticipated surgical resection. It may be particularly
valuable when bilateral adrenal masses are found
on imaging studies; however, it is technically diffi-
cult and should only be performed by an experi-
enced radiologist.
The presence of Cushing’s syndrome is sug-
gested on history and physical exam by the pres-
ence of easy bruisability, striae, post-cervical and
supraclavicular fat pads, menstrual irregularities,
and hyperglycemia. Again, presence of these find-
ings increases the pre-test odds of any screening
tests. Screening for this disorder depends upon
demonstration of high cortisol levels at a time when
one would expect the levels to be low. A normal
circadian rhythm results in a serum cortisol level
that is highest in the morning, but which is virtual-
ly immeasurable after midnight [25]. As it is logis-
tically difficult to obtain plasma samples on patients
at this late hour unless they are hospitalized, alter-
native diagnostic tests are necessary. Salivary lev-
els of cortisol have demonstrated excellent sensi-
tivity and specificity [26]. The patient should be
instructed to assume a recumbent posture and not
to eat, drink, or brush their teeth for at least one
hour prior to specimen collection. The patient col-
lects at least 1 cc of saliva into a sterile container
after midnight. The specimen should be refrigerat-
ed and dropped off at the lab the following morn-
ing. When the salivary cortisol level exceeds
550 ng/dL, the sensitivity and specificity of this test
are 92–100% and 96–100%, respectively [27].
In a hospitalized patient, serum cortisol levels ob-
tained after midnight exceeding 2 mcg/dL are also
strongly suggestive of the diagnosis with a 100%
sensitivity and specificity [28].
A confirmatory test for Cushing’s is a 24-hour
urine for creatinine and free cortisol. Cortisol ex-
cretion greater than three times the upper limit of
normal provides strong evidence of Cushing’s syn-
drome. The overnight 1 mg dexamethasone sup-
pression test provides another strong screening
tool. An 8 AM cortisol value > 1.8 mcg/dL after
a 1 mg dexamethasone dose the previous night is
highly suggestive of the diagnosis [29, 30]. Adreno-
corticotropic hormone (ACTH) levels then allow
differentiation between cortisol produced from an
autonomous adrenal neoplasm (ACTH concentra-
tion suppressed to < 1.1 pmol/L) and either a pitu-
itary (Cushing syndrome) or non-pituitary tumor
(ACTH-dependent). These findings should lead to
further biochemical testing and imaging studies to
confirm the diagnosis and localize the lesion [31].
Pheochromocytoma is a rare cause of resist-
ant or secondary hypertension. Its presence is sug-
gested by a history of frequent headaches, diaphore-
sis, paroxysmal tachycardia, and a family history of
pheochromocytoma, von-Hippel-Lindau disease, or
Multiple Endocrine Neoplasia Type II. The classic
means of screening for this has been a 24-hour urine
for creatinine and metanephrines. Plasma metane-
phrine and normetanephrine levels, however, pro-
vide better sensitivity and nearly equal specificity
(99% sensitivity and 89% specificity, respectively)
to the time honored 24-hour collection [32]. The
advantage of assaying metanephrines is that they
are produced continuously by pheochromocytomas,
resulting in steady-state levels, whereas catecho-
lamines are released only sporadically. A negative
test effectively excludes the diagnosis. Exceptions
include patients (usually encountered during
screening because of hereditary predisposition or
a previous history of pheochromocytoma) with
microscopic (< 1 cm) pheochromocytomas that pro-
duce only small amounts of catecholamines. Plasma
levels of free metanephrines are also relatively in-
dependent of renal function, making this a good
screening test for individuals with kidney failure [33].
Prior to any screening for pheochromocytoma, beta-
adrenoreceptor blocking drugs, phenoxybenzamine,
diuretics, tricyclic antidepressants, and monoamine
oxidase inhibitors should be discontinued. Aceta-
minophen should also be avoided for several days
prior to testing as it can lead to false positive re-
sults [33].
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As with any plasma tests to work up hyperten-
sion, the patient should be maintained in the supine
position and an intravenous indwelling venous cath-
eter should be placed 30 min prior to collection of
samples, thereby reducing the likelihood that pain
or stress will cause an elevation in catecholamine
levels. Plasma metanephrine levels > 1.4 pmol/mL
(> 2.5 fold above normal) and normetanephrine lev-
els > 2.5 pmol/mL (> 4 fold above normal) are high-
ly suggestive of the diagnosis. Patients with equiv-
ocally elevated plasma metanephrine and norme-
tanephrine levels should undergo a clonidine
suppression test [34]. This will distinguish weath-
er elevated catecholamine levels are a result of
augmented central sympathetic outflow (“nerv-
ous”) or a pheochromocytoma. A decrease in plas-
ma normetanephrine to more than 50% below base-
line or a level less than 2.96 nmol/L three hours
after an oral clonidine dose of 0.3 mg suggests
a centrally driven catecholamine elevation, not a phe-
ochromocytoma. A 24-hour urine sample for creati-
nine, metanephrines, free catecholamines, and va-
nillylmandelic acid, when done, are best obtained
within 24 hours after a crisis to catch the surge in
catecholamines secreted. However, this test suffers
from lack of sensitivity and specificity [32].
Marked elevation in plasma metanephrines or
normetanephrines, with a confirmatory clonidine
suppression test, if necessary, should lead to im-
aging studies for localization of the tumor.
Kidney-related causes
Renal artery stenosis (RAS) is the most com-
mon and well-recognized cause of resistant hyper-
tension. While renal artery stenosis can be caused
by fibromuscular dysplasia, the vast majority of
renal artery lesions are due to atherosclerosis.
Atherosclerotic RAS occurs more commonly in
elderly patients with a history of diffuse athero-
sclerotic cardiovascular disease, declining kidney
function, a history of smoking, and hypercholeste-
rolemia [35]. Other clinical clues to its presence
include unexplained kidney impairment in the set-
ting of a bland urinalysis, sudden onset of hyper-
tension in an individual less than 30 years old or an
acute exacerbation of previously well controlled hy-
pertension in a patient older than 55. Recurrent
episodes of “flash” pulmonary edema should also
raise clinical suspicion. For reasons that are poorly
understood, RAS is less likely to occur in the Afri-
can-American population [36].
Acute renal failure (ARF) defined by a > 30%
decrease in renal excretory function in response to
CEI or ARB can also provide a clinical clue to the
diagnosis [37]. While this occurs most commonly
in patients who have high-grade bilateral disease,
the clinician has to be aware of the possibility of
a stenosis in a dominant or a single kidney. ACEI-
or ARB-induced-ARF is not specific for RAS, how-
ever. Atherosclerotic disease in small pre-glomer-
ular vessels or afferent arteriolar narrowing due to
hypertension or chronic use of vasoconstrictive
agents like cyclosporine can also cause ARF in the
setting of renin-angiotensin blockade. While a bruit
may not always be heard over the renal arteries,
bruits over other central vessels including subcla-
vian, carotid, and femoral arteries suggests diffuse
vascular disease and increases the likelihood of
a renal artery lesion.
As CEI and ARB therapy used in conjunction
with a diuretic can effectively control hypertension
in the majority of patients with unilateral RAS [38],
diagnostic screening is only recommended if inter-
vention to correct a stenotic lesion is planned. Re-
sistance to antihypertensive therapy or progressive
renal functional impairment due to bilateral disease
are reasons to intervene. Diagnostic screening for
renal artery stenosis is best accomplished with either
magnetic resonance angiography (MRA) or Doppler
ultrasound [39–41], both of which can provide sen-
sitivity and specificity exceeding 90% though the
diagnostic accuracy of the latter is markedly oper-
ator dependent and limited in obese patients. Spi-
ral CT angiography is another reasonably accurate
method of screening for RAS [42]. It is less inva-
sive than standard angiography, but also places the
patient with kidney impairment at risk for contrast
nephropathy. As such, until recently, both MRA and
Doppler ultrasound have been considered the
screening test of choice in patients with significant
impairment in renal excretory function. However,
the safety of MRA has come into question with rec-
ognition of a condition called nephrogenic fibrosing
dermopathy (NFD), a scleroderma-like condition
that can develop on the skin of the extremities [43].
NFD is a rare, but potential complication of the
gadolinium-based MRA contrast agents when used
in patients with an estimated glomerular filtration
rate (GFR) less than 30 mL/min/1.73 m2. Its use in
patients with kidney function > 60 mL/min/1.73 m2
appears to be safe, however.
Prophylactic measures to reduce the like-
lihood of contrast-induced nephropathy are well
described [44] and should be taken in patients with
renal impairment prior to CT or conventional ang-
iography. Again, the sensitivity and specificity of
any of these tests is influenced by pre-test proba-
bility of the disease. Angiography should be
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reserved for patients in whom simultaneous en-
dovascular intervention is also planned.
Fibromuscular dysplasia should be suspected
in a younger hypertensive patients, particularly
women. Successful correction of a stenotic lesion
can obviate need for lifelong antihypertensive ther-
apy in these patients. If fibromuscular dysplasia is
suspected, angiography should be the primary di-
agnostic step as simultaneous angioplasty is cura-
tive, and both CT angiography and MRA have lim-
ited diagnostic value [45, 46]. Low sensitivity and
specificity of these non-invasive tests is attributa-
ble to the majority of fibromuscular lesions being
located in the mid and distal main renal artery at
times extending into intrarenal branches, which
may be less well visualized.
Coarctation of the aorta is an infrequent cause
of resistant hypertension in the adult population, but
is easy screened for during physical exam. Renal
ischemia caused by narrowed aortic lumen is usu-
ally amenable to blockade of the renin-angiotensin
system.
Chronic kidney disease (CKD) or reduced re-
nal excretory function can also be a cause for re-
sistant hypertension, mainly due to reduced fil-
tration of sodium and resulting extracellular
volume expansion [47]. Despite the latter, ede-
ma may be absent. An adequate challenge of diu-
retic therapy is therefore imperative in patients
with an estimated GFR less than 60 mL/min. Care-
ful monitoring of renal excretory function is im-
perative, however, as diuretic-induced decrease in
renal preload to afferent arterioles stiffened by
chronic hypertensive vascular changes can result
in significant deterioration in GFR. Both increased
activity of the renin-angiotensin system mediated
by regional ischemia in segments of kidney
scarred by various disease processes and renal-
derived increases in sympathetic nervous activi-
ty may also contribute to resistant hypertension
in this CKD [48].
Medication-related
Drug-drug interactions are another cause for
failed antihypertensive therapy. A plethora of pre-
scription and non-prescription agents can also off-
set the salutary effects of antihypertensive drugs.
Concurrent use of non-steroidal anti-inflammatory
drugs (NSAIDS) may confound the antihypertensive
effects of medications by their sodium retentive
properties [49]. Additionally, they may antagonize
the vasodilatory effects of prostaglandins. Pseu-
doephedrine, Ephedra, St. John’s Wort, and Ginseng
are all agents that may be vasoconstrictive via dif-
ferent mechanisms, thereby attenuating the effects
of antihypertensive medications [50].
Lifestyle factors
Non-adherence to medications, excessive in-
take of dietary sodium, excessive alcohol intake,
obstructive sleep apnea, and obesity are all patient-
related factors that can cause or contribute to re-
sistant hypertension.
While non-adherence is difficult to assess his-
torically, absence of known side effects to specific
antihypertensive therapy should raise suspicion
about compliance with medications. For example,
one would expect development of some hirsuitism
or increasing weight and edema after treatment
with minoxidil. Normokalemia on loop or thiazide
diuretic therapy in the absence of potassium sup-
plementation, CEI or ARB therapy should raise the
suspicion of non-compliance, especially in a setting
of poorly controlled hypertension. Volume deple-
tion driven both by diuretic- and pressure-induced
natriuresis would be expected to enhance aldoster-
one-mediated kaliuresis.
As demonstrated in the ALLHAT study, diu-
retic therapy is important to the success of any an-
tihypertensive regimen [51]. This is particularly
true in the treatment of resistant hypertension [52].
Ingestion of a diet high in sodium will offset most
antihypertensive regimens. Examination of a 24-hour
urine for creatinine (as a marker of collection ade-
quacy) and sodium will inform the clinician about
dietary compliance. Barring initiation of or a recent
change in dose of either a diuretic or an NSAID, and
assuming an otherwise steady physiologic state,
patients are generally in sodium balance. As such,
the amount of sodium ingested by a patient is a very
close approximate of what is excreted in the urine.
The total urinary sodium (reported as mmol of so-
dium and converted to mg of sodium by multiplica-
tion by 23, the gram molecular weight of sodium)
thus gives the clinician a close estimate of the in-
take of dietary sodium.
One frequently needs to depend upon family
members to get more accurate history with regard
to alcohol intake. Alcohol abuse is an important fac-
tor contributing to elevated blood pressure, al-
though the relationship between quantities of alco-
hol imbibed and degree of blood pressure
elevation.is unclear. The mechanism through which
alcohol elevates blood pressure also remains un-
clear, although increased vascular contractility,
perhaps due to increased vascular smooth muscle
cell calcium content, may play a role [53]. These
changes may be mediated by augmented sympathetic
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discharge driven by alcohol-induced corticotrophin-
releasing hormone release [54].
Likewise, a history of obstructive sleep apnea
(OSA) is best obtained from the bed partner. Obstruc-
tive sleep apnea is diagnosed by demonstration of
apnea and hypoxemia during a sleep study. Hyper-
tension in this disorder is driven by hypoxia-induced
activation of sympathetic nervous pathways [55].
Treatment with BIPAP has been shown in some
studies to reduce systolic blood pressure by as
much as 10 mm Hg [56]. Other studies have not
demonstrated similar success [57].
Obesity is reaching epidemic proportions in the
United States and around the world [58]. To a large
extent, its preponderance has accrued as a result
of decreased physical activity and increased caloric
intake. While obesity and associated insulin resist-
ance contribute to hypertension by multiple mech-
anisms, one of the main effects is to increase sym-
pathetic nervous system traffic [59]. Renin-angi-
otensin activity is augmented both by downstream
effects from the sympathetic nervous system (SNS)
activation and by adiposity itself. Sodium retention
then occurs as a result of enhanced SNS and RAS
effects on the kidney. While antihypertensive ther-
apy simultaneously directed at blocking the sym-
pathetic nervous system, the RAS and extracellu-
lar volume expansion can be implemented, the an-
tihypertensive response is at times ineffective.
Visceral obesity has also been associated with in-
creased aldosterone levels [60]. Successful treat-
ment of obesity-related hypertension with aldoster-
one antagonists suggests that mineralocorticoid
may also play a pathogenic role.
Treatment of resistant hypertension
If no apparent lifestyle, endocrine, kidney, or
medication-related cause for resistant hypertension
can be identified, the appropriateness of the failed
medical regimen should be examined. A rational reg-
imen of antihypertensive agents is important when
dissecting potential causes for treatment failure. The
major contributors to hypertension include the ren-
in-angiotensin axis SNS, and sodium-intracellular
calcium metabolism (Fig. 1). The first two contrib-
ute to vasoconstriction while sodium-calcium dys-
metabolism acts on the volume component [61]. Any
or all of these components may contribute to blood
pressure elevation in a particular patient. Clues to
their individual contributions can frequently be
gleaned from demographic, historical and physical
exam findings (Table 3). For example, resting tach-
ycardia may indicate overactivity of the SNS, and the
addition of a sympatholytic (i.e. clonidine) may be in
order. African-Americans, as a demographic group,
may have low renin hypertension perhaps due to
metabolic abnormalities that result in both excess
total extracellular sodium and intracellular calcium
levels [62]. This population is more likely to respond
to diuretics and calcium channel blockers (CCB) [63].
When considering a reasonable regimen of an-
tihypertensive medications for individuals already on
a multi-drug regimen, one must consider whether
all limbs of the hypertension axis have been ade-
quately blocked. For example, a potent vasodilator
like minoxidil will cause reactive increases in both
SNS traffic and renal sodium retention. As such, com-
plementary use of a sympatholytic and a diuretic
would be indicated. Sufficient diuretic therapy is
imperative and is a frequently under-appreciated
cause of resistant hypertension especially where
vasodilator therapy is used predominantly or exclu-
Figure 1. Factors influencing blood pressure (BP). Mo-
dified from Izzo JL et al. [61].
Table 3. Clinical clues to causes of resistant hypertension.
Clinical clue Finding Possible association Possible treatment
Demographics Black/elderly Low renin state/intracellular Diuretic/CCBs
calcium dysmetabolism
History Type A personality Sympathetic nervous Sympatholytics/
system activation /beta-blockade
Physical exam Tachycardia Sympathetic nervous Sympatholytics/
system activation /beta-blockade
Bruits/vascular disease Renal artery stenosis activation CEI/ARB
Edema Sodium/volume excess Diuretics
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sively. Utilization of multiple diuretics that effect
different limbs of sodium retention in the kidney
(loop and thiazide diuretics) may be necessary in
some patients. Close follow up of renal excretory
function, plasma bicarbonate, and potassium values
is imperative in these cases. Conversely, diuretic use
with concomitant volume depletion augments acti-
vation of the SNS and the renin-angiotensin system.
The resulting vasoconstriction can offset the diuretic
effect, increasing blood pressure. Addition of specific
vasodilator agents in this circumstance can result in
improved blood pressure control.
Duplicative therapy directed at any one partic-
ular limb of the blood pressure axis (i.e. use of both
an ACE-inhibitor and an ARB) should usually be
considered unreasonable therapy if other limbs have
not been addressed. Combined ACE-inhibitor-ARB
therapy provide utility only for synergy to attenu-
ate proteinuria in nephrotic patients and to improve
survival in congestive heart failure [64, 65]. Con-
versely, because of the different binding and phar-
macologic characteristics, combining different sub-
classes of CCB has been shown to be efficacious in
some hypertensive patients [66].
The use of treatment algorithms for managing
hypertension and rapid titration of therapy over
a short period of time may also be of benefit. In-
creasing the frequency with which patients are seen
in follow up has been shown to correlate with bet-
ter blood pressure control [67]. Other factors that
have been shown to improve hypertension control
include referral to a specialist in clinical hyperten-
sion, or management in a nurse-led clinic where
more frequent patient visits can often be accommo-
dated [68]. Changes instituted in the management
of resistant hypertension have included the up-ti-
tration of CCB to higher doses, and the initiation of
moderate doses of longer-acting thiazide diuretics.
Resistant hypertension can usually be controlled on
standard therapy with 4 to 5 medications, and appro-
priate titration of doses.
A trial of therapy with aldosterone receptor
antagonists may also be of benefit, particularly in
a setting of obesity-related hypertension. Visceral
obesity has been associated with increased aldos-
terone levels, the metabolic syndrome and hyper-
tension [69]. Aldosterone may play a greater role
in resistant hypertension than might be indicated
by either plasma or urinary aldosterone levels [70].
Novel approaches to treatment
Endothelin antagonists have been shown to
reduce systolic blood pressure in animal and human
models [71]. Endothelin is an endogenous peptide
that is mostly secreted by endothelial cells. It is
responsible for vasoconstriction and hypertrophy of
vascular smooth muscle. The endothelin antago-
nists, however, are still not clinically used in sys-
temic hypertension for concern of teratogenicity,
but they do have a role in the management of ad-
vanced heart failure and pulmonary hypertension.
The exciting feature about this group of drugs is the
fact that there is no rebound increase in heart rate
despite their vasodilator effect, a significant advan-
tage over the traditional vasodilators. There may
be a role for these drugs in resistant hypertension
in the future once their side effect profile is better
characterized. They may turn out to be especially
useful in obesity, renal failure and calcineurin-in-
duced hypertension [72].
Carotid stimulators [73, 74] provide an elegant
method for using the baroreceptor reflex to reduce
blood pressure. Electrical stimulation of the carot-
id baroreceptors reduces sympathetic tone via cen-
trally mediated reflexes. This leads to a reduction
in both systolic and diastolic blood pressure as well
as the resting heart rate. The newer devices are
adjustable via radiofrequency signals and are free
of the side effects of the more archaic models used
in the 1960’s. Thus far, this method has been used
only in limited situations involving markedly resist-
ant hypertension at academic centers with experi-
ence in inserting the device. However, the results
have been impressive with an average drop in systo-
lic and diastolic pressures of over 22 mm Hg and
18 mm Hg, respectively [71, 72]. It is foreseeable
that these devices and similar technology will be
increasingly relevant as the prevalence of resistant
hypertension increases and blood pressure targets
decrease.
The device RESPeRATE is another new entry
into the field of mechanical approaches to hyperten-
sion [75–78]. It consists of a control box containing
a microprocessor, a belt-type respiration sensor, and
headphones, which provide feedback to the patient
during breathing. The device analyzes the patient’s
breathing pattern and creates a personalized melo-
dy composed of 2 distinct tones — one tone for in-
halation and one for exhalation. As the patient syn-
chronizes breathing with the tones, the device grad-
ually prolongs the exhalation tone (primarily) and
slows the breathing rate to < 10 breaths/minute
(“slow deep breathing”). The device is indicated by
the US Food and Drug Administration (FDA) for the
reduction of stress and as an adjunctive therapy in
hypertension. It can be combined with standard
antihypertensive drugs and other nonpharmacologic
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interventions. It has been shown to reduce systolic
pressure by 10–15 mm Hg and diastolic pressure
by 5–10 mm Hg [79]. The mechanism of action is
related to increased tidal volume and stimulation of
pulmonary mechanoreceptors with slow, deep
breathing. These pulmonary mechanoreceptors in
turn activate central pathways to reduce sympathet-
ic tone, cause arteriolar dilation, and reduce heart
rate and blood pressure The barriers to use are cost
(average $250 per device) and lack of insurance
coverage.
Lastly, dark chocolate which is high in flavo-
noid content [80], appears to have a cardiovascular
protective effect through its effects on nitric oxide.
In a crossover study, investigators demonstrated
that dark but not white chocolate significantly re-
duced systolic pressure by an average of 12 mm Hg
and diastolic pressure by over 8 mm Hg. There also
seemed to be a positive effect on insulin resistance
and LDL levels. The high flavonoid content and the
procyanidin oligomers in red wine, tea and dark
chocolate may contribute to some of their putative
cardiovascular benefits.
Summary
Control of hypertension is perhaps the most
important physician-directed modifiable factor in
preventing stroke, heart, and kidney disease. As
blood pressure targets continue to be lowered, cli-
nicians need a reasonably accurate and streamlined
approach to ruling out secondary causes of hyper-
tension. In the absence of an apparent secondary
cause for hypertension, attention to individual pa-
tient characteristics, demographics, and physical
exam findings coupled with rational, targeted phar-
macotherapy and earnest attention to lifestyle mod-
ifications usually results in improved blood pressure
control.
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